ArticleFrontiers in neuroscience2026
Microglial Sestrin2 alleviates depressive-like behaviors and cognitive impairment in a YTHDF1-dependent manner.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the role of microglial Sestrin2 in chronic unpredictable stress (CUS)-induced depressive-like behaviors and cognitive impairment in mice, and to explore the upstream molecular mechanism underlying the abnormal expression of microglial Sestrin2. Methods: Microglia-specific overexpression of Sestrin2 was achieved by injecting adeno-associated virus (AAV) into the CUS mouse hippocampus. Depressive-like behaviors were assessed using sucrose preference, tail suspension, and forced swim tests. Cognitive function was evaluated by the Morris water maze. Levels of IL-1β and IL-6 in the hippocampus and cell supernatants were measured by ELISA. BV2 microglial cells were used for Results: Sestrin2 expression was significantly reduced in the hippocampus of CUS mice. Overexpression of Sestrin2 specifically in microglia ameliorated CUS-induced depressive-like behaviors, cognitive impairment, and inflammatory levels. YTHDF1 expression was also reduced in the CUS hippocampus. Mechanistically, YTHDF1 bound to Sestrin2 mRNA and knockdown of YTHDF1 decreased Sestrin2 expression. Molecular biology prediction results showed that positions 1943 and 2,114 of Sestrin2 mRNA are high-confidence N Conclusion: Microglial Sestrin2 alleviates depressive-like behaviors, cognitive impairment and neuroinflammation. YTHDF1 regulates Sestrin2 expression via an m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.